Research programme: retinoic acid metabolising enzyme blockers - BioenvisionAlternative Names: RAMBA - Bioenvison
Latest Information Update: 16 Mar 2007
At a glance
- Originator Bioenvision
- Mechanism of Action Retinoic acid metabolism modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Leukaemia; Prostate cancer
Most Recent Events
- 05 Nov 2003 Preclinical trials in Leukaemia in USA (unspecified route)
- 05 Nov 2003 Preclinical trials in Prostate cancer in USA (unspecified route)